



## CooperVision® Expands MiSight® 1 day to Cover Nearly 100% of Spherical Prescriptions for Children with Myopia

*Expanded Range of up to -7.00D Makes Myopia Control a Possibility for More Age-Appropriate Children Than Ever Before*



**Richmond Hill, ON Canada., June 16, 2022**—CooperVision today announced that its MiSight® 1 day contact lenses will be available in higher prescriptions in June 2022. The expanded range—covering -0.50D to -7.00D (0.50D steps after -6.00D) in Canada and the U.S.— means that MiSight® 1 day covers approximately 99% of prescriptions for all children who have myopia and less than 0.75D of astigmatism.<sup>[1]</sup> The diopter extension for this innovative, specially designed lens will allow even more children to benefit from myopia management.

MiSight® 1 day contact lenses are backed by the longest-running soft contact lens study among children. The clinical trial has proven that MiSight® 1 day works for nearly all children with myopia,<sup>[2]</sup> cuts myopia progression by half,<sup>[3]</sup> works at any age a child starts treatment (8+),<sup>[3]</sup> works for as long as the child wears them as recommended<sup>[3]</sup> and data indicates that there is no rebound effect with MiSight® 1 day contact lenses.<sup>[4],[5]</sup>

With myopia on the rise globally,<sup>[6]</sup> an increasing number of children may require the higher prescriptions that MiSight® 1 day lenses will offer.

“Every diopter matters, particularly for children whose myopia progression may have already placed them at a higher risk for conditions such as myopic maculopathy and glaucoma.<sup>[7]</sup> While early treatment is best, it’s never too late to start,” said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision, “Even older children starting with MiSight® 1 day have seen their myopia progression cut by half.”<sup>[3]</sup>

As a global leader in myopia control and management for children, CooperVision believes that options must be available for as many children as possible. With MiSight® 1 day's range extension, Eye Care Professionals in Canada and in more than 30 other countries can have an even greater impact.

# # #

\*Canadian Indications for Use: MiSight (omafilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study. Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MiSight (omafilcon A) Soft Contact Lenses for Myopia Control are indicated for single use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.

°Includes prescriptions up to 0.75DC.

†90% of myopic eyes respond to MiSight® 1 day treatment; ages 11-15 at start of wear, n=90.

§Using measured and modeled data, pooled across ages (8-17), MiSight® 1 day slowed myopia progression by an average of approximately 50%.

||Children with myopia fit with MiSight® 1 day contact lenses ages 8-15 continued to experience slowed myopia progression as long as they remained in treatment.

¶ On average, for children aged 8-15 at start of wear. Instead, eye growth reverted to expected, age average myopic progression rates.

### **About CooperVision**

CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit [www.coopervision.ca](http://www.coopervision.ca).

### **About CooperCompanies**

CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit [www.coopercos.com](http://www.coopercos.com).

### **Media Contact**

Hannah Barry, Counselor, McDougall Communications  
[hannah@mcdougallpr.com](mailto:hannah@mcdougallpr.com) or +1-585-645-8985

---

<sup>[1]</sup> CVI Data on file, 2022. SERE coverage of childhood myopia prescriptions with MiSight® 1 day for 104,810 eyes in Asia (China, Korea) and 116,336 eyes in Europe and USA aged 8-18 years.

<sup>[2]</sup> Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. *Optom Vis Sci* 2022 In Press.

<sup>[3]</sup> Arumugam B, Bradley A, Hammond D, Chamberlain P. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. *Invest. Ophthalmol. Vis. Sci.* 2021;62(8):2333.

<sup>[4]</sup> Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. *Optom Vis Sci* 2021;98:E-abstract 210049.

<sup>[5]</sup> Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. *Optom Vis Sci* 2021;98:E-abstract 215130.

<sup>6</sup> Holden et al, Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. *Ophthalmology* 2016. 123(5):1036-1042.

<sup>7</sup> Bullimore et al. Myopia Control: Why Each Diopter Matters *Optom Vis Sci* 2019;96:463–465.

+++